Dexmedetomidine

Detomax is a relatively selective alpha2-adrenergic agonist indicated for: Sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Administer Detomax by continuous infusion not to exceed 24 hours. Sedation of non-intubated patients prior to and/or during surgical and other procedures.

Dexmedetomidine is a specific and selective alpha-2 adrenoceptor agonist. By binding to the presynaptic alpha-2 adrenoceptors, it inhibits the release if norepinephrine, therefore, terminate the propagation of pain signals. Activation of the postsynaptic alpha-2 adrenoceptors inhibits the sympathetic activity decreases blood pressure and heart rate.

Individualize and titrate Dexmeditomidine dosing to desired clinical effect. Administer Dexmeditomidine using a controlled infusion device. Dilute the 200 mcg/2 mL (100 mcg/mL) vial contents in 0.9% sodium chloride solution to achieve required concentration (4 mcg/mL) prior to administration. The 200 mcg/50 mL single-use bottles do not require further dilution prior to administration. For Adult Intensive Care Unit Sedation : Generally initiate at one mcg/kg over 10 minutes,  followed by a maintenance infusion of 0.2 to 0.7 mcg/kg/hour. For Adult Procedural Sedation : Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion initiated at 0.6 mcg/kg/hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hour. Alternative Doses : Recommended for patients over 65 years of age and awake fiberoptic intubation patients.